跳转至内容
Merck
CN
所有图片(1)

主要文件

AB5334P

Sigma-Aldrich

Anti-Synuclein α Antibody

Chemicon®, from sheep

登录查看公司和协议定价


About This Item

UNSPSC代码:
12352203
eCl@ss:
32160702
NACRES:
NA.41

生物来源

sheep

质量水平

抗体形式

affinity purified immunoglobulin

抗体产品类型

primary antibodies

克隆

polyclonal

纯化方式

affinity chromatography

种属反应性

rat, human

制造商/商品名称

Chemicon®

技术

immunohistochemistry: suitable (paraffin)
western blot: suitable

UniProt登记号

运输

dry ice

靶向翻译后修饰

unmodified

基因信息

human ... SNCA(6622)

特异性

Recognizes alpha synuclein.

免疫原

Synthetic peptide corresponding amino acids 116-131 of human alpha synuclein.

应用

Detect Synuclein using this Anti-Synuclein Antibody, α validated for use in WB, IH(P).
Immunohistochemistry: 0.5-1 μg/mL on frozen or paraffin sections.

Western blot: 0.5-1 μg/mL

Optimal working dilutions must be determined by the end user.
Research Category
Neuroscience
Research Sub Category
Neurodegenerative Diseases

联系

Replaces: 04-1053

外形

Affinity purified immunoglobulin in PBS containing 0.02% sodium azide. Lyophilized. Reconstitute with 50 μL of sterile distilled water. Centrifuge to remove any residue. Glycerol (1:1) can be added for additional stability.

储存及稳定性

Maintain lyophilized material at -70°C (dry) for up to 12 months. After reconstitution maintain at -20°C in undiluted aliquots for up to 6 months. Avoid repeated freeze/thaw cycles.

法律信息

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

免责声明

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

未找到合适的产品?  

试试我们的产品选型工具.

储存分类代码

13 - Non Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Edward I Ginns et al.
Molecular genetics and metabolism, 111(2), 152-162 (2014-01-07)
Clinical, epidemiological and experimental studies confirm a connection between the common degenerative movement disorder Parkinson's disease (PD) that affects over 1 million individuals, and Gaucher disease, the most prevalent lysosomal storage disorder. Recently, human imaging studies have implicated impaired striatal
A highly reproducible rotenone model of Parkinson's disease.
Cannon, JR; Tapias, V; Na, HM; Honick, AS; Drolet, RE; Greenamyre, JT
Neurobiology of Disease null
Yong-Ren Chen et al.
International journal of molecular sciences, 21(11) (2020-05-31)
Parkinson's disease (PD) is a long-term degenerative disease of the central nervous system (CNS) that primarily affects the motor system. So far there is no effective treatment for PD, only some drugs, surgery, and comprehensive treatment can alleviate the symptoms
Lojze M Smid et al.
Journal of Alzheimer's disease : JAD, 36(2), 261-274 (2013-04-10)
This work is aimed at correlating pre-mortem [18F]FDDNP positron emission tomography (PET) scan results in a patient with dementia with Lewy bodies (DLB), with cortical neuropathology distribution determined postmortem in three physical dimensions in whole brain coronal sections. Analysis of
Hazel L Roberts et al.
PloS one, 12(2), e0171925-e0171925 (2017-02-12)
α-Synuclein misfolding and aggregation is often accompanied by β-amyloid deposition in some neurodegenerative diseases. We hypothesised that α-synuclein promotes β-amyloid production from APP. β-Amyloid levels and APP amyloidogenic processing were investigated in neuronal cell lines stably overexpressing wildtype and mutant

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门